C07D 239/86
With hetero atoms directly attached in position 4
Official title: with hetero atoms directly attached in position 4
C07D239/86 (With hetero atoms directly attached in position 4) appears on 1,321 US grants and 1,485 published applications in this corpus.
Search patents in C07D- Granted patents
- 1,321
- Published applications
- 1,485
- Assignees
- 728
- Inventors
- 4,582
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 11 | 0 |
| 1977 | 3 | 0 |
| 1978 | 8 | 0 |
| 1979 | 8 | 0 |
| 1980 | 9 | 0 |
| 1981 | 10 | 0 |
| 1982 | 3 | 0 |
| 1983 | 6 | 0 |
| 1984 | 8 | 0 |
| 1985 | 5 | 0 |
| 1986 | 4 | 0 |
| 1987 | 11 | 0 |
| 1988 | 8 | 0 |
| 1989 | 7 | 0 |
| 1990 | 4 | 0 |
| 1991 | 4 | 0 |
| 1992 | 11 | 0 |
| 1993 | 19 | 0 |
| 1994 | 20 | 0 |
| 1995 | 24 | 0 |
| 1996 | 12 | 0 |
| 1997 | 19 | 0 |
| 1998 | 35 | 0 |
| 1999 | 25 | 0 |
| 2000 | 19 | 0 |
| 2001 | 33 | 7 |
| 2002 | 32 | 34 |
| 2003 | 31 | 45 |
| 2004 | 22 | 79 |
| 2005 | 23 | 86 |
| 2006 | 40 | 62 |
| 2007 | 44 | 67 |
| 2008 | 33 | 77 |
| 2009 | 34 | 71 |
| 2010 | 45 | 90 |
| 2011 | 51 | 58 |
| 2012 | 51 | 62 |
| 2013 | 66 | 64 |
| 2014 | 62 | 71 |
| 2015 | 63 | 69 |
| 2016 | 52 | 62 |
| 2017 | 60 | 59 |
| 2018 | 49 | 43 |
| 2019 | 43 | 60 |
| 2020 | 42 | 56 |
| 2021 | 32 | 42 |
| 2022 | 28 | 48 |
| 2023 | 16 | 59 |
| 2024 | 24 | 54 |
| 2025 | 31 | 33 |
| 2026 | 21 | 27 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Membrane-active anti-bacterial compounds and uses thereof29 Sep 2026US 12,747,213 B2Regents of the University of Minnesota
- Quinazoline-4(3H)-one derivatives as negative allosteric modulators of metabotropic glutamate receptor 225 Aug 2026US 12,715,879 B2Vanderbilt University
- Crystalline form, and process for its production11 Aug 2026US 12,703,688 B1Alterity Therapeutics Limited
- Methods and compositions for targeting Tregs using CCR8 inhibitors28 Jul 2026US 12,692,239 B2Nanjing Immunophage Biomedical Co., Ltd.
- Heterocyclic compounds as kinase inhibitors for therapeutic uses30 Jun 2026US 12,668,584 B2National Health Research Institutes
- Compound comprising n-methylpiperazine ethanol carbamate structure and use thereof1 Oct 2026US 2026/0297037 A1Korea Institute of Radiological & Medical Sciences
- Modulators of sortilin activity24 Sep 2026US 2026/0285802 A1
- Piperazinyl-Modified Quinazolinyl-Aryl Urea Derivative, And Preparation Method And Use Thereof24 Sep 2026US 2026/0285816 A1Guangxi Normal University
- New compounds and treatment of renal cell carcinoma27 Aug 2026US 2026/0248788 A1Trustlife Therapeutics Inc.
- Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors27 Aug 2026US 2026/0250304 A1Riboscience LLC
Most cited
By later US patents
- Alkynyl and azido-substituted 4-anilinoquinazolines379US 5,747,498 APfizer Inc. · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Quinazoline derivatives217US 5,770,599 AZeneca Limited · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998